0001654954-17-008377.txt : 20170912 0001654954-17-008377.hdr.sgml : 20170912 20170912163038 ACCESSION NUMBER: 0001654954-17-008377 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170707 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170912 DATE AS OF CHANGE: 20170912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954078884 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 171081411 BUSINESS ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 8-K 1 ptn_8k.htm CURRENT REPORT Blueprint
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 7, 2017
 
Palatin Technologies, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
001-15543
95-4078884
(State or other jurisdiction
(Commission
(IRS employer
of incorporation)
File Number)
identification number)
 
4B Cedar Brook Drive, Cranbury, NJ
08512
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (609) 495-2200
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company   
 
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
 

 
 
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
(d)          On September 7, 2017, the Board of Directors (the “Board”) of Palatin Technologies, Inc. (“Palatin” or the “Company”) appointed Anthony M. Manning, Ph.D., to the Board, effective September 7, 2017, and concurrently fixed the number of members of the Board at eight. Mr. Manning will hold office until the date of the Company’s next annual meeting of stockholders, or until his earlier death, resignation or removal. The Board has determined that Mr. Manning satisfies the definition of “independent” director, including, without limitation, the applicable requirements of the NYSE MKT Listing Rules and the Securities Exchange Act of 1934, as amended. The committee or committees of the Board to which Mr. Manning will be appointed has not been determined.
 
The Board granted Mr. Manning an initial restricted stock unit award for 54,000 shares of Palatin’s common stock, par value 0.01 per share (the “common stock”), and an initial stock option award for 54,000 shares of Palatin common stock exercisable at $0.50 per share, each of which vest ratably over four years in annual installments. As a non-employee director, Mr. Manning will receive compensation in the same manner as the Company’s other non-employee directors, including an annual retainer of $40,000 for service on the Board.
 
There are no arrangements or understandings between Mr. Manning and any other person pursuant to which he was appointed as a member of the Board. There are no family relationships between Mr. Manning, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission) between Mr. Manning and the Company.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits
 
 99.1 Press release, dated September 12, 2017.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PALATIN TECHNOLOGIES, INC.
 
 
Date: September 12, 2017
By:
/s/ Stephen T. Wills                                                            
 
 
Stephen T. Wills, CPA, MST
 
 
Executive Vice President, Chief Financial
 
 
Officer and Chief Operating Officer
 
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit No.
 
Description
 
 
 
 
Press release, dated September 12, 2017.
 
 
 
 
 
 
 
 
 
EX-99.1 2 ptn_ex991.htm PRESS RELEASE Blueprint
EXHIBIT 99.1
Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to
Board of Directors
 
CRANBURY, N.J., September 12, 2017 -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to Palatin’s Board of Directors on September 7, 2017. Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.
 
"We are pleased to welcome Anthony to our Board," said John Prendergast, Ph.D., Chairman of the Board of Palatin Technologies. "Anthony is an accomplished pharmaceutical executive with extensive experience translating research into innovative products. Earlier this year we licensed bremelanotide, our Phase 3 treatment for female sexual dysfunction, to AMAG Pharmaceuticals. As we now begin to focus on the development of our earlier stage assets, Anthony will provide valuable insights and perspective with respect to our research, development and business strategy."
 
Dr. Manning, age 55, is responsible for research and the discovery of novel products as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. Since joining Momenta, his team has advanced three novel autoimmune drugs into development. Prior to Momenta, Dr. Manning was Vice President and Head of Immunology Research for Biogen Idec, Inc. Before that, he was Vice President and Global Head of Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals.
 
Anthony M. Manning holds a Ph.D. from the University of Otago, New Zealand, and has authored more than 100 peer-reviewed publications and patents in the fields of signal transduction, autoimmune diseases and drug discovery.
 
Davis Board Consultants of Boston, MA assisted in the search.
 
About Palatin Technologies, Inc.
 
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com.
 
 
Palatin Technologies Investor Inquiries:
Stephen T. Wills, CPA, MST
 
Chief Operating Officer/Chief Financial Officer
 
Tel: (609) 495-2200/info@palatin.com
 
Palatin Technologies Media Inquiries:
Paul Arndt, MBA, LifeSci Advisors, LLC
 
Managing Director
 
Tel: (646) 597-6992 / Paul@LifeSciAdvisors.com
 
###